TipRanks
Advertisement
Advertisement

ALDX Stock Latest News

Analyst Maintains Hold on Aldeyra Amid FDA Uncertainty Over Reproxalap’s Regulatory Path
RatingsAnalyst Maintains Hold on Aldeyra Amid FDA Uncertainty Over Reproxalap’s Regulatory Path
1M ago
ALDX
Aldeyra Therapeutics Leases New Concord Headquarters Space
PremiumCompany Announcements
Aldeyra Therapeutics Leases New Concord Headquarters Space
2M ago
8K
ALDX
ALDX Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
ALDX Upcoming Earnings Report: What to Expect?
2M ago
ALDX
Aldeyra Therapeutics Adds Independent Director, Affirms Governance Support
PremiumCompany Announcements
Aldeyra Therapeutics Adds Independent Director, Affirms Governance Support
3M ago
8K
ALDX
Shareholders Sue Aldeyra Therapeutics Over Dry Eye Drug Claims
PremiumMarket News
Shareholders Sue Aldeyra Therapeutics Over Dry Eye Drug Claims
4M ago
ALDX
Aldeyra Updates Reproxalap Outlook and Extends Cash Runway
PremiumCompany AnnouncementsAldeyra Updates Reproxalap Outlook and Extends Cash Runway
5M ago
8K
ALDX
Aldeyra Therapeutics Faces Securities Lawsuit Over Reproxalap Trial Disclosures 
Premium
Class Action
Aldeyra Therapeutics Faces Securities Lawsuit Over Reproxalap Trial Disclosures 
5M ago
ALDX
Aldeyra Therapeutics Announces Upcoming Board Member Departure
Premium
Company Announcements
Aldeyra Therapeutics Announces Upcoming Board Member Departure
5M ago
8K
ALDX
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky
PremiumClass Action
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky
5M ago
ALDX
Aldeyra Therapeutics Sued Over Alleged Misrepresentations About Key Drug Trial Data
PremiumClass Action
Aldeyra Therapeutics Sued Over Alleged Misrepresentations About Key Drug Trial Data
6M ago
ALDX
Aldeyra Repays Hercules Loan, Boosting Financial Flexibility
PremiumCompany Announcements
Aldeyra Repays Hercules Loan, Boosting Financial Flexibility
6M ago
8K
ALDX
Maintaining Hold on Aldeyra as FDA CRL Clouds Reproxalap’s Dry Eye Path and Lowers Approval Odds
PremiumRatings
Maintaining Hold on Aldeyra as FDA CRL Clouds Reproxalap’s Dry Eye Path and Lowers Approval Odds
6M ago
ALDX
Aldeyra downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe FlyAldeyra downgraded to Neutral from Buy at H.C. Wainwright
6M ago
ALDX
Morning News Wrap-Up 3/17/26: Today’s Biggest Stock Market Stories!
Premium
Market News
Morning News Wrap-Up 3/17/26: Today’s Biggest Stock Market Stories!
6M ago
MA
MU
FDA issues Aldeyra CRL saying reproxalap NDA failed to demonstrate efficacy
Premium
The Fly
FDA issues Aldeyra CRL saying reproxalap NDA failed to demonstrate efficacy
6M ago
ALDX
How Did the FDA Shatter Investor Confidence In Aldeyra Therapeutics Stock (ALDX) Today?
PremiumMarket News
How Did the FDA Shatter Investor Confidence In Aldeyra Therapeutics Stock (ALDX) Today?
6M ago
ALDX
FDA Issues Second Complete Response Letter for Reproxalap
PremiumCompany Announcements
FDA Issues Second Complete Response Letter for Reproxalap
6M ago
8K
ALDX
Aldeyra options imply 10.9% move in share price post-earnings
PremiumThe Fly
Aldeyra options imply 10.9% move in share price post-earnings
7M ago
ALDX
Aldeyra Therapeutics Announces Chief Development Officer Resignation
PremiumCompany Announcements
Aldeyra Therapeutics Announces Chief Development Officer Resignation
9M ago
8K
ALDX
Aldeyra Therapeutics: Buy Rating Affirmed Amid Promising Drug Development and Robust Investment Potential
PremiumRatingsAldeyra Therapeutics: Buy Rating Affirmed Amid Promising Drug Development and Robust Investment Potential
9M ago
ALDX
Midday Fly By: Ford takes $19.5B EV writedown, Apple expanding iPhone lineup
Premium
The Fly
Midday Fly By: Ford takes $19.5B EV writedown, Apple expanding iPhone lineup
9M ago
F
F
Buy Rating for Aldeyra Therapeutics: Confidence in Reproxalap’s Approval and Financial Upside
Premium
Ratings
Buy Rating for Aldeyra Therapeutics: Confidence in Reproxalap’s Approval and Financial Upside
9M ago
ALDX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >